Behavioral Health Market to Cross Valuation of US$ 262 Bn by 2031; Growing Need for Treating Substance Abuse Disorders Underpins Abundant Avenues: TMR Study
June 06, 2022 12:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 06, 2022 (GLOBE NEWSWIRE) -- The global market study on behavioral health market is witnessing steady creation of lucrative opportunities on the back of...
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
May 04, 2022 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Insights on the Mental Health Apps Global Market to 2027: Featuring Sanvello Health, Flow Neuroscience and Youper Among Others
April 21, 2022 05:08 ET
|
Research and Markets
Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Global Mental Health Apps Market Size, Share & Industry Trends Analysis Report By Application, By Platform Type (iOS, Android, and Others), By...
Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
April 07, 2022 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company developing therapies to treat central nervous system (CNS)...
Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
February 28, 2022 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Zai Lab and Karuna Therapeutics Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
November 09, 2021 07:00 ET
|
Zai Lab Limited; Karuna Therapeutics
Zai Lab obtains exclusive rights to develop and commercialize KarXT in Greater China Karuna to receive upfront cash payment of $35 million, up to $152 million in potential near- and long-term...
Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
November 08, 2021 07:30 ET
|
Minerva Neurosciences, Inc
Company to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company...
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
November 01, 2021 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Promotion of Geoff Race to President
October 11, 2021 08:30 ET
|
Minerva Neurosciences, Inc
Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc....
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
September 30, 2021 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...